MedVector on StartEngine | Deal Review

May 3, 2021 1 min read
MedVector - Telemedicine for Clinical Trials
Transforming Clinical Trials

MedVector Campaign's Highlights

MedVector is an industry-first telemedicine platform that greatly accelerates clinical trials.

By connecting subjects from anywhere in the world to existing clinical trial sites, MedVector has proven to exponentially increase clinical trial participation and dramatically accelerate FDA approval.

Our service generates revenue for doctors and hospitals, reduces costs to clinical trial sponsors, and brings life-changing, advanced medicine to the market more quickly.

Below a few highlights from the company's StartEngine campaign:

  • The Clinical Trials Market is currently worth ~$47 billion, with a predicted value of $104 billion based on our extensive research.
  • We have one of the world's largest clinical trial networks, obtaining access to 7 hospitals consisting of hundreds of thousands of patients per year.
  • During our case studies with Novartis, our progress greatly excelled against traditional patient recruitment services. In just 7 weeks we were able to do what often takes years.

Did I Invest In MedVector?

I’m still in the process of writing a full deal report and decide whether or not I will invest in MedVector. I review 100+ pitches on 10+ platforms every month and send a detailed report every Saturday to subscribers of the Angel Notes newsletter (you can join through the form below). See you soon!

Great! Next, complete checkout for full access to Angel Notes.
Welcome back! You've successfully signed in.
You've successfully subscribed to Angel Notes.
Success! Your account is fully activated, you now have access to all content.
Success! Your billing info has been updated.
Your billing was not updated.